Placeholder Banner

BIO Comments on Facilitating Competition and Innovation in the Biological Products Marketplace

September 21, 2018

BIO submitted comments for the Food and Drug Administration (FDA) public hearing on Facilitating Competition and Innovation in the Biological Products Marketplace, which took place on September 4, 2018. BIO remarked on the need to foster a robust, competitive marketplace for biological products to improve patient access to safe, effective, and affordable therapies. BIO unequivocally believes that safe and effective biosimilars and interchangeable products are good for patients and good for public health.

BIO's detailed comments cover topics as they relate to the biosimilars market including interchangeability, analysis of analytical similarity, patented and unpatented uses,  regulatory exclusivity, and the Purple Book.

 

Download Full Comments Below
FINAL BIO Commet Letter Biosimilars Part 15 Public Hearing 9-21-18
Read full comment letter below
Discover More
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the U.S. Senate Committee on Health, Education, Labor, and Pensions’ (Committee’s) Request for Information on Improving and Protecting Access to Gene Therapies…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Department of Health and Human Services’ (HHS’) proposed Notice of Benefit and Payment Parameters (NBPP) for 2025.
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Centers for Medicare & Medicaid Services’ Draft CY 2025 Part D Redesign Program Instructions.